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Abstract 28 
Objective: This study aims to determine if the prognostic significance of troponins in acute 29 
coronary syndrome in predicting mortality varies by age, and if so, to what extent when other 30 
prognostic indicators are considered. 31 
Methods: We analysed Myocardial Ischemia National Audit Project registry data collected 32 
between January 2006 and December 2010 and followed up this cohort for all-cause 33 
mortality until August 2011. Relationships between peak troponin levels (types I and T) and 34 
time to death in different age groups, and between age and time to death at different troponin 35 
levels were investigated using multiple variable adjusted Cox regression models.   36 
Results: Of the 322,617 patients with acute coronary syndromes included, a third 37 
(n=106,365, 33%) died during 695,334 person-years of follow-up. Within each troponin 38 
category, older age was associated with a higher mortality even in those with a troponin 39 
<0.01 ng/ml for both troponin types (HR ~10-12 in ≥85 years cf. HR of 1.0 in <65 years). 40 
The relative potency of an elevated troponin to predict an adverse outcome compared to a 41 
low troponin attenuated with increased age (for troponin I ≥15.0 compared to troponin I 42 
<0.01 in age <65, adjusted HR 2.41 (95% confidence interval (CI) 1.80-3.24); age ≥85 HR 43 
2.01 (1.62-2.52)). Similar but less consistent results were observed with troponin T elevation 44 
at the higher levels. 45 
Conclusion: Clinicians should interpret the prognostic value of troponin taking into account 46 
the patient’s age.  47 
48 
 49 
Key questions 50 
What is already known about the subject? 51 
• The prognostic significance of cardiac troponin is well documented but little research 52 
has focused on whether this varies with age. 53 
What does this study add? 54 
• We found the risk of mortality in older patients were very high compared to the 55 
younger patients even among patients with the lowest troponin levels. 56 
• The magnitude of risk of mortality with similarly high troponin levels tended to 57 
decrease in older age group compared to younger age group. 58 
How might this impact clinical practice? 59 
• Clinicians should interpret the prognostic value of troponins taking into account of the 60 
patient’s age.  61 
62 
Introduction  63 
 Cardiac troponins are both sensitive and specific markers of myocardial cell damage 64 
and have prognostic significance in acute coronary syndrome, with higher levels predicting 65 
worse outcomes.[1,2] Recent evidence suggests that  levels of troponin I as low as 0.012-66 
0.049 ng/ml carry a significant risk of recurrent myocardial infarction or death compared to a 67 
troponin I level of <0.012.[3] However, it is not known whether troponins have equal or more 68 
or less prognostic value in patients  aged 65-84 years compared to those who are older (85+ 69 
years) and those who are younger (<65 years).  70 
 71 
 Understanding the prognostic significance of troponins in older patients is important 72 
as there is a rapidly ageing population in developed world societies yet most clinical trials 73 
exclude patients with very old age.  Acute coronary syndrome (ACS) is also more prevalent 74 
in older age and recent work by our group[4,5] and others[3] suggest that even a minimal rise 75 
in troponin may be associated with worse outcomes in older patients. Therefore it is likely 76 
that a troponin rise in older age may have a different prognostic value compared to those who 77 
are younger and may vary even within the older age spectrum.  78 
 79 
 Therefore, we aimed to address two related research questions: (1) does the 80 
prognostic significance of troponins in ACS in predicting mortality vary by age, and if so, (2) 81 
to what extent, when other prognostic indicators such as age, sex, co-morbidities, treatment 82 
receipt and site and level of care are also considered? 83 
84 
 85 
Methods 86 
Study design and population 87 
 This was a cohort study of all patients aged 18 years or over in the United Kingdom 88 
Myocardial Ischemia National Audit Project (MINAP) database admitted to all 230 NHS 89 
hospital trusts in England and Wales between January 2006 and December 2010 who had a 90 
confirmed diagnosis of an acute coronary syndrome. For the purposes of this study, eligibility 91 
criteria were defined as any ACS as determined by the medical teams at time of discharge, 92 
including ST-segment elevation myocardial infarction (STEMI) and other acute coronary 93 
syndromes (non-ST elevation myocardial infarction (Non-STEMI), troponin negative ACS, 94 
threatened and unconfirmed myocardial infarction). The outcome was all-cause mortality 95 
outcome at follow up of up to August 2011. We deliberately excluded entries to MINAP prior 96 
to 2006 as the use of primary percutaneous coronary intervention in the UK was less than 97 
10% before 2006.[6] Mortality was ascertained through linkage with the Office of National 98 
Statistics.[7] 99 
 100 
Data collection 101 
 The MINAP dataset is contributed to by all 230 NHS trusts in England and Wales and 102 
uses a standardised data format that allows examination of pre-hospital and in-hospital care 103 
of all acute coronary syndromes, and is a part of the NHS data dictionary.[8] The 104 
development and initial findings of MINAP have been previously reported.[9,10] The dataset 105 
was collected by nurses and clinical audit staff and contains 123 fields.[11]  The subset of 106 
variables included and description of variables are described in Data Supplement 1. We used 107 
the cut offs of <65, 65-74, 75-84 and ≥85 years as age groups.  Furthermore, we defined 108 
participants who were <65 years as young, participants who were 65-74 years as younger 109 
elderly, 75-84 years as older elderly and ≥85 as oldest old. 110 
 111 
Statistical methods 112 
 We investigated associations between troponin levels, age group and other prognostic 113 
variables using Spearman correlation test for continuous variables, Cuzick non-parametric 114 
test for trend for binary variables and chi square test for other categorical variables. We 115 
estimated the independent effects of prognostic variables on time to death using Cox 116 
proportional hazards models. To assess the proportionality of hazards between age or 117 
troponin subgroups and outcomes, postestimation complementary log-log plots were 118 
constructed.  All analyses were performed using Stata statistical software (Version 10.1, 119 
StatCorp, USA).   120 
 121 
Missing values of variables other than troponin measurements were imputed using multiple 122 
imputation by chained equation method in STATA, assuming that data were missing at 123 
random.[12.13]  In fact, previous imputation analyses on the MINAP dataset[14] have not 124 
significantly altered effect sizes and imply that missing data in MINAP is at random whilst 125 
work by others has also shown that the level of missing data  does not alter regional 126 
standardised mortality ratios.[15] 127 
 128 
 Troponin I and T levels were used in the imputations, but for the statistical analyses 129 
patients with missing troponin levels were excluded from the respective analyses. We 130 
analysed 10 imputed datasets, with point estimates and standard errors calculated using 131 
Rubin's rules.[16] Analysis of baseline characteristics of participants was restricted to the 132 
complete data only but the Cox regression analyses presented results of the imputed data.   133 
 134 
 Analysis was stratified by the type of troponin measured (I and T) and age group 135 
(<65, 65-74, 75-84 and ≥85 years).  For each troponin type, we re-categorised six categories 136 
(troponin specific) based on pre-specified cut off points. The cut off points for troponin I 137 
were <0.01, 0.01-0.049, 0.05-0.49, 0.5-2.49, 2.5-14.99 and ≥15.0. For troponin T the cut off 138 
points were <0.01, 0.01-0.049, 0.05-0.099, 0.1-0.49, 0.5-1.79 and ≥1.8).  These cut off points 139 
represent respective percentile values equivalent to each other; the troponin I cut off points 140 
were predetermined first based on clinically meaningful cut off points at lower levels and 141 
then 25th, 50th and 75th centile values and the equivalent troponin T values were determined 142 
based on similar percentile values.  143 
 144 
 The explanatory variables in the Cox models were  troponin I or T levels, age group, 145 
sex, BMI, current smokers, family history of heart disease, STEMI or non-STEMI, co-146 
morbidities (hypertension, diabetes, MI, angina, stroke, heart failure, chronic renal failure, 147 
peripheral vascular disease), previous PCI, previous CABG, serum cholesterol, serum 148 
glucose, troponin group, medications prior to admission (aspirin, ACEi, beta-blocker, statin, 149 
clopidogrel), speciality of consultant in charge at the time of admission and admission ward.  150 
All of these variables were independently associated with time to death in the full models. 151 
We adjusted for medications that patients had been taking on admission because there were 152 
potential confounders that could affect survival.  However, we did not include in the 153 
multivariate model medications that were started after the admission because there could 154 
have been a causal relationship between admission and subsequent death or survival.  155 
 156 
 We additionally tested whether age modified the effect of troponin and vice versa by 157 
adding age-troponin interaction variables to the Cox models, assessing statistical significance 158 
using Wald chi-squared tests. Hazard ratios for troponin within each age stratum and for age 159 
within each troponin stratum were estimated using linear combinations of terms after each 160 
regression.  161 
162 
Results 163 
 A total of 424,848 patient records were available in the MINAP registry over 5 years 164 
(2006-2010).  After exclusion of patients with missing troponin and mortality data and those 165 
with a final diagnosis of non-ACS chest pain, the study cohort consisted of 322,617 166 
participants.  Peak troponin I and T were measured in 186,988 participants and 135,629 167 
participants respectively. The mean age of the entire cohort was 70.0±14.0 years and 208,343 168 
participants (65%) were men. The mean follow up was just over 2.0 years (789±564 days; 169 
695,334 person-years; median follow up 706 days (inter quartile range 308-1227 days).   170 
 171 
 The characteristics of the study sample by peak troponin specific group stratified by 172 
different age groups are shown in Table 1. There were a decreasing proportion of men, 173 
current smokers and participants with a positive family history of heart disease with older age 174 
groups.  In all age groups, the most common known co-morbidities were hypertension and 175 
hyperlipidaemia, the former more common with older age, the latter less common.  Older age 176 
was significantly associated with prevalence of prior cardiovascular disease and chronic renal 177 
failure. Prior PCI was most prevalent in participants from the youngest age group whilst prior 178 
CABG was most prevalent in those aged 65-84 years.  With regards to peak troponin levels, 179 
lower levels of peak troponins were observed with older age.  Except for aspirin, all other 180 
cardiac medication specific to ACS were used significantly less frequently in older age 181 
groups. Younger patients were more likely to be treated by a cardiologist and admitted to a 182 
coronary care unit. The proportion of patients with a confirmed diagnosis of STEMI 183 
decreased with age.  The characteristics of the study sample stratified by peak troponin 184 
categories are shown in Supplementary Table 1.  A total of 106,365 patients (33%) died 185 
during the follow-up. The crude mortality of oldest old (≥85 years) was very high compared 186 
to those <65 years; >60% vs. 7-8% during the overall follow-up (Supplementary Figure 1). 187 
Mortality at 1-year were 44.5% and 4.6%, respectively. Comparing this to expected mortality 188 
of the same age categories of general population in the UK (data source: Office of National 189 
Statistics. Death registration by single year of age 190 
http://www.ons.gov.uk/ons/rel/vsob1/death-registrations-by-single-year-of-age/united-191 
kingdom-2011/index.html) confirms the disproportionate incremental increase with older age 192 
(see Supplementary Figure 2).  193 
 194 
 The hazard ratios for mortality in older age groups compared to the youngest age 195 
group, stratified by troponins levels, are shown in Table 2 and Figure 1. Within each troponin 196 
category, older age was associated with a higher mortality and whilst adjusting for all 197 
potential confounders attenuated the higher risk of death with increased age, the results 198 
remained highly significant statistically. Even in the lowest category level of troponins I and 199 
T (<0.01 ng/ml), older patients had very high mortality compared to younger patients (HRs 200 
for oldest old age group (≥85 years) compared to young age group (<65 years; reference 201 
hazard ratio of 1.00) showed adjusted HRs 11.70 and 9.24 respectively for troponin I and T). 202 
The age-troponin interaction term was statistically significant for both troponin I and troponin 203 
T models (P<0.0001).  204 
 205 
 The hazards ratios of mortality associated with troponin levels stratified by age are 206 
shown in Table 3 and Figure 2. Higher troponin levels were associated with increasing risk of 207 
mortality in all age groups. However, the relative potency of an elevated troponin to predict 208 
an adverse outcome compared to a low troponin attenuated with increased age (for troponin I 209 
≥15.0 compared to troponin I <0.01 in age <65, adjusted HR 2.41 (95% confidence interval 210 
(CI) 1.80-3.24); age ≥85 HR 2.01 (1.62-2.52)). A similar attenuation was observed for 211 
troponin T up to troponin levels of 0.1; however at levels higher than 0.1, the relative potency 212 
of troponin to predict an adverse outcome did not attenuate with increased age.  213 
 214 
Secondary sensitivity analyses by additionally adjusting for discharge medications and 215 
reperfusion strategies in the model did not alter the results (data not shown). 216 
 217 
The Cox proportional hazards assumptions were met for all outcome analyses.  218 
219 
Discussion 220 
 Our results showed that in any age group, higher troponin levels were associated with 221 
increasing risk of mortality. We found very high mortality rates in older patients even at the 222 
lowest troponin values. There was an attenuation of the prognostic value of troponins in older 223 
age. Thus, the prognostic value of troponins depends on patient age in acute coronary 224 
syndrome.  225 
 226 
 The very high mortality rates in older patients even at the lowest troponin values 227 
usually regarded as normal (<0.04) may be partly explained by frailty and other unknown 228 
confounders; there may also be differences in care delivered for older patients with ACS as 229 
with increasing age, we found cardiac medication specific to ACS were used significantly 230 
less frequently in older age groups. Our observations show that older patients are less likely 231 
to be managed by cardiologists, less likely to be managed in coronary care units, intensive 232 
care units and cardiac wards.  Other studies have also found that older patients were more 233 
likely to receive medical treatments[17] and are less likely to receive evidence-based 234 
treatments, including myocardial revascularisation therapy.[18]  Therefore, the higher 235 
mortality we report in the older patient with ACS might be associated with poor physiological 236 
reserve, frailty and increased co-morbidity but equally may be driven by lesser receipt of 237 
evidence-based treatments and the fact they tend to be managed with a more conservative 238 
strategy compared to younger patients.  239 
 240 
 Due to  uncertainties around the benefits of the invasive interventions,  despite their 241 
higher risk of adverse clinical outcomes following ACS, older patients may often be managed 242 
with more conservative strategies compared to younger patients.[19] Although, there is 243 
evidence to suggest that adherence to guideline-recommended therapy is associated with a 244 
decrease in mortality,[20]   the management of ACS in older age is challenging.  It is well 245 
documented that older patients are more likely to present atypically compared to younger 246 
patients with ACS[21]  and it has been suggested that there are  high misdiagnosis rates and 247 
inappropriate discharge rates for ACS particularly in older populations.[22,23]   Our study is 248 
limited to those who were entered into the MINAP registry and this might have introduced 249 
some selection bias and thus the estimated hazard risks in the oldest old might have been 250 
underestimated.  251 
 252 
 We found interestingly that even with the lowest troponin levels in ACS, the risk of 253 
death in older patients was very high compared to younger counterparts. The exact reason for 254 
this is unclear. A recent cohort study suggests that lowering the troponin I threshold using the 255 
lowest percentile as cut off point would identify more patients with acute coronary syndrome 256 
who are at risk of recurrent myocardial infarction and death.[3] It is possible that patients 257 
with lowest troponin had myocardial damage but because the peak troponin value was not 258 
very high they were not adequately investigated and treated. However, we adjusted for a large 259 
number of potential confounders. 260 
  261 
 We have previously found that “incidental rises in troponin” in older patients in the 262 
absence of evidence of ACS and any other known causes of troponin elevation predicted 263 
outcomes comparable to those of someone having had an ACS.[5] We postulated that the 264 
minimal rise in cardiac troponins in such circumstances may be related to myocardial 265 
necrosis and perhaps served as a prognostic marker indicating cardiac frailty in older patients 266 
with general illness other than an ACS. Studies suggest that even mild transient elevations of 267 
troponin levels are associated with increased mortality and major cardiovascular events in the 268 
general population.[24,25] It has been suggested that microvascular coronary artery disease 269 
in congestive heart failure, diabetes and chronic kidney disease may cause troponin 270 
elevations.  In heart failure, left ventricular strain, decreased subendothelial  perfusion, 271 
endothelial dysfunction and apoptosis may cause troponin rises and microvascular disease are 272 
known to occur in diabetes and chronic kidney disease.[25]  In addition, older people may not 273 
have as high a troponin rise as in younger people despite having a similar extent of cardiac 274 
damage because age related physiological changes in cardiac myocytes may influence the 275 
response to injury.   276 
 277 
 For the first time, we report the attenuation of the prognostic value of troponins in 278 
older age.  It is possible that this attenuation may be apparent due to very high baseline risk in 279 
older patients even in the troponin values which fell within normal reference range. The other 280 
plausible reason behind this is that with increasing age, the global risk factor profile worsens 281 
and thus these competing risks may attenuate the prognostic significance of troponins in older 282 
age. Clinicians should be aware that troponin values in isolation do not provide the whole 283 
prognostic outlook of the patient. 284 
    285 
 Our study has several strengths.  First, we analysed a large sample which captures 286 
sufficient variations of patients in all ages and troponin levels. As the MINAP data is based 287 
on all NHS trusts in England and Wales, the findings are representative of UK and Western 288 
populations in general. Secondly, we were able to adjust for individual prognostic factors and 289 
a variety of potential confounding factors which may affect mortality outcome. We were also 290 
able to consider both troponins I and T separately, and have shown similar results in both 291 
allowing us more confidence in the validity of these findings. Furthermore, we included 292 
patients since 2006 only to allow comparison to contemporary standards of management of 293 
ACS.  294 
 295 
Study limitations 296 
 Our study has some limitations.  First, most patients had some prognostic data 297 
missing, which we replaced using multiple imputation and meant we were unable to 298 
undertake a complete dataset analysis. The primary outcome was all-cause mortality and we 299 
were unable to determine if the cause of death was related to a cardiac pathology. Although 300 
we have adjusted for several potential confounders, there remains the possibility of residual 301 
confounding.  Whilst we were able to take into account whether the initial care was delivered 302 
by a cardiologist or non-cardiologist, we could not establish if the subsequent care may have 303 
involved a cardiologist.  One other limitation was that we did not have information on 304 
reperfusion therapy for patients.  However, previously analyses within MINAP have reported 305 
that receipt of evidence-based cardiac medications post ACS is less in older age groups,[26] 306 
and we expect that our cohort will be similar to other cohorts in literature where it has been 307 
reported that younger patients are more likely to receive reperfusion therapy.[27]  Another 308 
limitation was that we do not have information on time to therapy as we expect that delay in 309 
presentation may be associated with delayed treatment and worse outcomes. However chest 310 
pain in older person is usually associated with a heart attack compared to a younger person 311 
and we have no reason to believe age would have influenced the health seeking behaviour 312 
particularly with regard to chest pain. 313 
 314 
Future studies 315 
 Future studies should evaluate the prognostic value of re-defining the cut off points 316 
for troponins based on the patient’s age.  Furthermore, randomised trials should examine 317 
whether targeted assessments and interventions would improve the outcome in patients in 318 
older age with ACS including those with minimal troponin rise regardless of the clinical 319 
diagnosis.  These future randomised studies should also consider the feasibility, clinical and 320 
cost effectiveness of individually tailored specialised management of ACS in older age, who 321 
currently remain at high risk following ACS but have concomitantly less specialist cardiology 322 
input.  323 
 324 
Conclusions 325 
 In conclusion, we have shown that the prognostic significance of troponin in ACS 326 
attenuates with increased age and that older age is associated with a worse prognosis 327 
compared to younger counterparts given the same level of troponin rise, even at very low 328 
levels of troponin.  Therefore, the age of the patient should be taken into consideration when 329 
assessing the prognosis of a patient given a raised troponin value for prognostication in ACS 330 
based on this evidence.   331 
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Table and Figure legends 424 
Table 1: Troponin assay specific baseline characteristics of 322,617 men and women of the 425 
MINAP acute coronary syndrome cohort (2006-2011) according to age category by different 426 
troponin assays  427 
Table 2: Troponin specific unadjusted and adjusted hazards ratios and their corresponding 428 
95% confidence intervals for the risk of mortality for people in the older age groups 429 
compared to the people in the youngest age group (<65 years) within troponin strata 430 
Table 3: Unadjusted and adjusted hazards ratios and their corresponding 95% confidence 431 
intervals for mortality for higher troponin level categories compared to the lowest level of 432 
troponin (<0.01 ng/ml) within the same age strata 433 
 434 
Supplementary Table 1: Troponin assay specific baseline characteristics of 322,617 men 435 
and women of the MINAP acute coronary syndrome cohort (2006-2011) according to 436 
different troponin categories 437 
 438 
Supplementary Table 2: Comparison of baseline characteristics of the included and 439 
excluded cohort 440 
 441 
Figure 1: Adjusted hazards ratios (95% confidence intervals) of mortality according to 442 
various age groups within troponin strata 443 
 444 
Figure 2: Adjusted hazard ratios (95% confidence intervals) of mortality according to various 445 
levels of peak troponin categories within age strata 446 
 447 
Supplementary Figure 1: Crude mortality rates (95% confidence intervals) at follow up 448 
(August 2011) in different age groups by peak troponin categories 449 
Supplementary Figure 2: Crude mortality rates (95% confidence intervals) compared to 450 
expected mortality of similar age categories at follow up (August 2011) for the oldest and 451 
youngest age groups by peak troponin categories  452 
 453 
Data Supplement 1: MINAP description of variables in analysis and definitions of variables 454 
 455 
Table 1: Troponin assay specific baseline characteristics of 322,617 men and women of the MINAP acute coronary syndrome cohort (2006-
2011) according to age category by different troponin assays  
 
Variable* Troponin I cohort (n=186,988) Troponin T cohort (n=135,629) 
Age group (years) <65 
(n=65,761) 
65-74 
(n=44,564) 
75-84 
(n=49,611) 
≥85 
(n=27,052) 
P 
value‡ 
<65 
(n=47,123) 
65-74 
(n=31,527) 
75-84 
(n=36,163) 
≥85 
(n=20,816) 
P-value† 
Men 51,292 (78) 29,831 (67) 27,762 (56) 11,576 (43) <0.0001 36,984 (79) 21,272 (68) 20,475 (57) 9,151 (44) <0.0001 
BMI (kg/m2) 29 (6) 28 (6) 26 (5) 24 (5) <0.0001 29 (6) 28 (5) 26 (5) 25 (5) <0.0001 
Current smokers 29,413 (47) 9,362 (22) 5,134 (11) 1,191 (5) <0.0001 22,359 (49) 7,125 (24) 4,027 (12) 977 (5) <0.0001 
IMD score 23 (16) 21 (15) 20 (15) 19 (14) <0.0001 27 (17) 25 (17) 23 (16) 22 (15) <0.0001 
Family history of 
heart disease 
26,881 (47) 11,499 (32) 7,945 (21) 2,218 (11) <0.0001 19,105 (49) 8,216 (35) 6,087 (24) 1,915 (15) <0.0001 
Prior co-morbidities 
Hyperlipidemia 23,196 (37) 17,366 (41) 16,805 (36) 6,231 (25) <0.0001 15,022 (35) 11,501 (40) 11,593 (35) 4,822 (26) <0.0001 
Hypertension 26,122 (41) 23,823 (55) 28,673 (60) 14,763 (57) <0.0001 17,792 (40) 16,029 (54) 20,214 (59) 11,138 (57) <0.0001 
Diabetes 10,444 (16) 10,908 (25) 12,119 (25) 4,629 (18) <0.0001 7,054 (15) 7,603 (25) 8,510 (24) 3,556 (18) <0.0001 
MI 12,631 (20) 12,916 (30) 16,876 (35) 9,284 (35) <0.0001 8,331 (19) 8,413 (28) 11,781 (34) 6,842 (35) <0.0001 
Angina 13,149 (21) 14,803 (35) 19,868 (42) 11,090 (43) <0.0001 9,422 (21) 10,103 (34) 14,382 (42) 8,570 (44) <0.0001 
Heart failure 1,116 (2) 2,160 (5) 4,327 (9) 3,463 (13) <0.0001 849 (2) 1,600 (5) 3,289 (10) 2,679 (14) <0.0001 
Stroke 2,235 (4) 3,860 (9) 6,149 (13) 3,823 (15) <0.0001 1,645 (4) 2,738 (9) 4,567 (14) 3,025 (16) <0.0001 
Chronic renal failure 1,262 (2) 2,155 (5) 4,140 (9) 2,742 (11) <0.0001 1,000 (2) 1,515 (5) 2,911 (9) 1,999 (10) <0.0001 
PVD 1,756 (3) 2,378 (6) 2,874 (6) 1,207 (5) <0.0001 1,319 (3) 1,755 (6) 2,334 (7) 994 (5) <0.0001 
Prior interventions 
PCI 7,530 (12) 5,671 (13) 4,666 (10) 1,088 (4) <0.0001 5,042 (12) 3,585 (12) 3,012 (9) 729 (4) <0.0001 
CABG 2,926 (5) 4,456 (10) 4,588 (10) 948 (4) <0.0001 1,892 (4) 2,922 (10) 3,124 (9) 712 (4) <0.0001 
Biochemical results 
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Troponin (ng/ml) 16.8 (27.3) 14.1 (24.5) 12.7 (23.1) 11.8 (21.9) <0.0001 3.11 (13.23) 2.91 (13.26) 2.77 (12.64) 2.79 (14.10) <0.0001 
Cholesterol (mmol/L) 5.2 (1.6) 4.6 (1.5) 4.3 (1.5) 4.2 (1.6) <0.0001 5.2 (1.6) 4.6 (1.6) 4.3 (1.6) 4.1 (1.7) <0.0001 
Glucose (mmol/L) 7.9 (4.6) 8.4 (4.7) 8.5 (4.6) 8.4 (4.5) <0.0001 8.1 (5.4) 8.6 (5.5) 8.7 (5.4) 8.4 (4.6) <0.0001 
Admission medications 
ACE inhibitor 17,689 (30) 16,642 (42) 20,199 (46) 10,098 (41) <0.0001 12,550 (30) 11,517 (41) 14,619 (45) 7,734 (41) <0.0001 
Beta blocker 14,745 (25) 13,331 (34) 16,107 (36) 8,350 (34) <0.0001 10,760 (26) 9,142 (33) 11,644 (36) 6,557 (35) <0.0001 
Statin 21,869 (36) 20,911 (52) 24,429 (54) 10,940 (44) <0.0001 15,875 (37) 14,711 (51) 17,801 (54) 8,452 (44) <0.0001 
Clopidogrel 5,279 (15) 4,365 (19) 4,997 (19) 2,446 (18) <0.0001 5,020 (18) 3,698 (20) 4,565 (21) 2,419 (20) <0.0001 
Aspirin 36,256 (55) 26,241 (59) 28,556 (58) 14,674 (54) 0.414 26,282 (56) 18,607 (59) 20,973 (58) 11,568 (56) 0.109 
Management, setting and diagnosis 
Cardiologist as lead 
consultant 
34,088 (53) 20,480 (47) 18,570 (38) 7,086 (27) <0.0001 26,091 (56) 15,557 (50) 14,899 (42) 6,767 (33) <0.0001 
Admission ward 
CCU 
ITU 
Cardiac ward 
Other 
 
36,448 (60) 
959 (2) 
5,544 (9) 
19,262 (31) 
 
21,426 (51) 
775 (2) 
3,979 (9) 
15,773 (38) 
 
19,830 (43) 
636 (1) 
4,254 (9) 
21,150 (46) 
 
8,373 (34) 
150 (1) 
2,038 (8) 
13,748 (57) 
 
<0.0001 
 
30,521 (67) 
778 (2) 
2,948 (7) 
11,102 (24) 
 
17,932 (60) 
538 (2) 
2,236 (8) 
9,077 (30) 
 
17,474 (53) 
487 (1) 
2,505 (8) 
12,626 (38) 
 
7,872 (43) 
119 (1) 
1,384 (8) 
8,763 (48) 
 
<0.0001 
 
Diagnosis 
STEMI 
ACS but not STEMI 
 
27,022 (41) 
38,739 (59) 
 
13,706 (31) 
30,858 (69) 
 
11,972 (24) 
37,639 (76) 
 
5,328 (20) 
21,724 (80) 
 
<0.0001 
 
22,054 (47) 
25,069 (53) 
 
11,361 (36) 
20,166 (64) 
 
10,206 (28) 
25,957 (72) 
 
4,716 (23) 
16,100 (77) 
 
<0.0001 
Outcome 
Death at follow up 4,398 (7) 8,793 (20) 18,991 (38) 16,181 (60) <0.0001 3,593 (8) 6,818 (22) 15,394 (43) 13,367 (64) <0.0001 
 
* Results reported as mean (SD) for continuous variables and n (%) for categorical variables.  † Spearman correlation test for continuous variables, Chi square 
test for admission ward, Cuzick non-parametric test for trend for binary variables were used. BMI = body mass index; IMD = index of multiple deprivation; 
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MI= myocardial infarction; PVD= peripheral vascular disease; PCI = percutaneous coronary intervention, CABG = coronary artery bypass graft, CCU = 
coronary care unit, ITU = intensive care unit, STEMI = ST elevation myocardial infarction, ACS = acute coronary syndrome  
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Table 2: Troponin specific unadjusted and adjusted hazards ratios and their corresponding 95% confidence intervals for the risk of mortality for 
people in the older age groups compared to the people in the youngest age group (<65 years) within troponin strata  
 
Troponin I (n=185,510) 
Age 
group 
Unadjusted hazards ratio (95% CI) 
<0.01  0.01-0.049  0.05-0.49  0.5-2.49  2.5-14.99 ≥15.0 All troponin I levels 
<65 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
65-74 3.49 (2.46-4.97) 2.74 (2.14-3.52) 3.18 (2.92-3.46) 3.17 (2.92-3.45) 3.31 (3.09-3.56) 3.26 (3.05-3.49) 3.23 (3.11-3.35) 
75-84 7.28 (5.20-10.19) 5.42 (4.30-6.84) 6.63 (6.14-7.16) 6.78 (6.29-7.31) 7.60 (7.13-8.11) 7.78 (7.32-8.27) 7.25 (7.01-7.49) 
≥85 19.45 (13.56-27.91) 13.07 (10.07-16.95) 12.56 (11.62-13.58) 13.55 (12.56-14.62) 14.36 (13.45-15.32) 15.82 (14.86-16.84) 14.29 (13.81-14.79) 
 Adjusted hazards ratio (95% CI)*  
<65 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
65-74 2.90 (2.04-4.13) 2.25 (1.76-2.89) 2.50 (2.30-2.72) 2.46 (2.27-2.68) 2.64 (2.46-2.84) 2.72 (2.54-2.91) 2.61 (2.51-2.71) 
75-84 5.32 (3.79-7.46) 3.91 (3.10-4.93) 4.43 (4.10-4.79) 4.51 (4.18-4.88) 5.18 (4.84-5.54) 5.50 (5.16-5.87) 4.97 (4.78-5.16) 
≥85 11.70 (8.14-16.81) 8.20 (6.31-10.65) 7.34 (6.76-7.97) 8.19 (7.55-8.87) 8.63 (8.04-9.26) 9.77 (9.12-10.46) 8.59 (8.22-8.97) 
Troponin T (n=134,547) 
Age 
group 
Unadjusted hazards ratio (95% CI) 
<0.01  0.01-0.049 0.05-0.099  0.1-0.49  0.5-1.79  ≥1.8  All troponin T levels 
<65 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
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65-74 2.58 (2.16-3.09) 2.87 (2.35-3.50) 2.75 (2.34-3.23) 3.24 (3.02-3.49) 3.20 (2.95-3.48) 3.09 (2.86-3.35) 3.13 (3.00-3.26) 
75-84 6.27 (5.33-7.38) 6.05 (5.06-7.23) 6.03 (5.22-6.97) 6.97 (6.52-7.45) 7.67 (7.11-8.27) 7.43 (6.92-7.97) 7.24 (6.98-7.52) 
≥85 11.84 (9.90-14.17) 10.35 (8.63-12.41) 11.12 (9.63-12.85) 12.89 (12.05-13.78) 14.86 (13.77-16.04) 15.67 (14.57-16.85) 13.96 (13.44-14.49) 
 Adjusted hazards ratio (95% CI)* 
<65 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
65-74 2.19 (1.83-2.63) 2.26 (1.86-2.76) 2.17 (1.85-2.55) 2.55 (2.36-2.74) 2.52 (2.32-2.75) 2.55 (2.36-2.76) 2.50 (2.39-2.61) 
75-84 4.74 (4.02-5.60) 4.03 (3.37-4.82) 3.96 (3.43-4.58) 4.64 (4.33-4.97) 5.08 (4.70-5.49) 5.19 (4.83-5.58) 4.83 (4.63-5.04) 
≥85 9.24 (7.69-11.11) 6.20 (5.15-7.45) 6.60 (5.69-7.66) 7.69 (7.16-8.26) 8.82 (8.12-9.58) 9.48 (8.78-10.25) 8.27 (7.89-8.66) 
* adjusted for age group, sex, body mass index, current smokers, family history of heart disease, STEMI or non-STEMI, co-morbidities 
(hypertension, diabetes, MI, angina, stroke, heart failure, chronic renal failure, peripheral vascular disease), previous PCI, previous CABG, 
serum cholesterol, serum glucose, troponin group, admission medications (aspirin, ACEi, beta-blocker, statin, clopidogrel), admission 
consultant, admission ward. 
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Table 3: Unadjusted and adjusted hazards ratios and their corresponding 95% confidence intervals for mortality for higher troponin level 
categories compared to the lowest level of troponin (<0.01 ng/ml) within the same age strata 
Troponin I (n=185,510) Unadjusted hazards ratio (95% CI) 
<65  65-74  75-84 ≥85 All troponin I levels 
<0.01  1.00 1.00 1.00 1.00 1.00 
0.01-0.049  1.13 (0.79-1.60) 0.88 (0.69-1.14) 0.84 (0.68-1.04) 0.76 (0.58-1.00) 0.92 (0.81-1.05) 
0.05-0.49  1.89 (1.40-2.55) 1.72 (1.40-2.12) 1.72 (1.45-2.05) 1.22 (0.98-1.52) 2.20 (1.98-2.45) 
0.5-2.49  2.16 (1.61-2.91) 1.96 (1.59-2.41) 2.01 (1.69-2.39) 1.59 (1.26-2.02) 2.68 (2.41-2.98) 
2.5-14.99  2.14 (1.59-2.87) 2.03 (1.65-2.49) 2.23 (1.88-2.66) 1.58 (1.27-1.96) 2.72 (2.44-3.02) 
≥15.0 2.10 (1.56-2.81) 1.96 (1.59-2.40) 2.24 (1.88-2.67) 1.71 (1.37-2.12) 2.33 (2.09-2.59) 
 Adjusted hazards ratio (95% CI)* 
<0.01  1.00 1.00 1.00 1.00 1.00 
0.01-0.049  1.23 (0.86-1.74) 0.95 (0.74-1.23) 0.90 (0.73-1.12) 0.86 (0.65-1.13) 0.94 (0.83-1.07) 
0.05-0.49 1.95 (1.45-1.63) 1.69 (1.37-2.08) 1.63 (1.36-1.94) 1.23 (0.98-1.53) 1.56 (1.40-1.73) 
0.5-2.49 2.22 (1.65-2.99) 1.89 (1.53-2.33) 1.89 (1.58-2.25) 1.64 (1.29-2.08) 1.85 (1.66-2.06) 
2.5-14.99 2.26 (1.69-3.04) 2.06 (1.68-2.54) 2.21 (1.85-2.63) 1.67 (1.34-2.08) 2.05 (1.84-2.28) 
≥15.0 2.41 (1.80-3.24) 2.27 (1.84-2.79) 2.50 (2.09-2.98) 2.01 (1.62-2.52) 2.34 (2.10-2.61) 
Troponin T (n=134,547) Unadjusted hazards ratio (95% CI) 
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<65  65-74 75-84 ≥85 All troponin T levels 
<0.01  1.00 1.00 1.00 1.00 1.00 
0.01-0.049  1.77 (1.43-2.19) 1.97 (1.67-2.32) 1.71 (1.52-1.92) 1.55 (1.34-1.78) 2.32 (2.15-2.49) 
0.05-0.099  2.08 (1.72-2.52) 2.22 (1.91-2.57) 2.00 (1.80-2.23) 1.96 (1.72-2.23) 2.81 (2.63-3.01) 
0.1-0.49 1.95 (1.68-2.27) 2.45 (2.17-2.77) 2.17 (1.98-2.38) 2.45 (2.10-2.85) 2.98 (2.81-3.15) 
0.5-1.79 1.80 (1.55-2.10) 2.24 (1.97-2.54) 2.20 (2.00-2.42) 2.26 (2.00-2.55) 2.78 (2.62-2.95) 
≥1.80 1.87 (1.62-2.18) 2.25 (1.99-2.56) 2.22 (2.02-2.45) 2.49 (2.20-2.81) 2.47 (2.33-2.62) 
 Adjusted hazards ratio (95% CI)* 
<0.01  1.00 1.00 1.00 1.00 1.00 
0.01-0.049  1.78 (1.44-2.20) 1.83 (1.56-2.16) 1.51 (1.34-1.70) 1.19 (1.03-1.38) 1.49 (1.39-1.61) 
0.05-0.099 2.04 (1.69-2.47) 2.02 (1.74-2.34) 1.71 (1.53-1.90) 1.46 (1.27-1.67) 1.73 (1.61-1.85) 
0.1-0.49  1.92 (1.65-2.23) 2.23 (1.97-2.52) 1.88 (1.71-2.06) 1.83 (1.56-2.14) 1.88 (1.77-1.99) 
0.5-1.79 1.91 (1.64-2.22) 2.19 (1.93-2.49) 2.04 (1.85-2.25) 1.82 (1.60-2.06) 2.03 (1.91-2.16) 
≥1.80 2.19 (1.88-2.54) 2.54 (2.24-2.89) 2.39 (2.17-2.64) 2.24 (1.97-2.55) 2.40 (2.26-2.55) 
* adjusted for age group, sex, body mass index, current smokers, family history of heart disease, STEMI or non-STEMI, comorbidities 
(hypertension, diabetes, MI, angina, stroke, heart failure, chronic renal failure, peripheral vascular disease), previous PCI, previous CABG, 
serum cholesterol, serum glucose, troponin group, admission medications (aspirin, ACEi, beta-blocker, statin, clopidogrel), admission 
consultant, admission ward. 
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